Cencora is set to invest $1bn by 2030 to expand its US pharmaceutical distribution network, adding resilience and capacity.

Here are three important regulatory changes affecting parenteral packaging that pharmaceutical companies need to be aware of ...

The guidance change marks the latest adjustment Novo has made to its 2025 outlook as the company battles a changing market.

Leukogene Therapeutics has received orphan drug designation from the US FDA for M2T-CD33 (LTI-214), its immunotherapy candidate targeting AML.

Avant Technologies and SGAustria have announced a joint venture (JV) and licence agreement to advance a therapy for diabetes ...

ADCs remain à la mode in the oncology sector, with Merck & Co (MSD) tying up another deal to advance its pipeline in the ...

Both companies have upped their offers for Metsera amid a bidding war, but Novo Nordisk comes armed with an extra $1.9bn.

Agentic AI was a point of emphasis on the first day of the 2025 Veeva Commercial summit held in Madrid, Spain.

Expanding Access to Lyophilized Therapies: Reunite removes reliance on vial kits and manual reconstitution, making ...

Ensuring fair drug pricing was a key promise of Sri Lanka’s government’s election manifesto, and that promise is finally ...

The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and Drug ...

Alvotech, with its strategic commercialisation partner Advanz Pharma, received EMA approval for Mynzepli (AVT06) in August ...